SGLT-2 inhibitors were associated with a lower incidence of death from any cause among patients with CKD, compared with placebo: RR 0.87 (95% CI 0.80–0.95; P = 0.003) (Supplemental Fig. 5 and Table 3). This evidence concerns the gene SLC5A2 and chronic kidney disease.